NanoViricides is trading 5.2% down today at $1.53 as the stock undergoes consolidation following a significant multi-day run.
- The recent momentum was fueled by bullish clinical progress for NV-387 and a new Outperform rating with a $6.00 price target.
- Today's decline appears to be driven by profit-taking, with no fresh company-specific news or regulatory filings reported so far.